BIOS
BIOS Health is a UK-based neural engineering company that builds AI-driven neural interfaces and an AI dosing platform (NeuroTune) to read and write the body's nervous system signals in real time, serving pharmaceutical firms, neuromodulation device makers, healthcare providers, and academic medical centers.
- Company typePrivate
- Founded2015
- HeadquartersCambridge, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What BIOS does
BIOS Health Ltd is a Cambridge, UK-based neural engineering company founded in 2015 by Cambridge University researchers Emil Hewage and Oliver Armitage. The company develops AI-driven neural interface technology that reads and writes the body's neural signals in real-time, with the stated goal of building "neural digital therapies" as a new class of precision medicine. Its core platform combines proprietary neural interfaces with machine learning, including Bayesian optimization (NeuroTune), neural biomarker discovery, and a Remote Health Platform that pairs wearables with mobile apps to capture cardiac and autonomic biomarkers. The technology is positioned as functionally analogous to DNA sequencing for the nervous system, supporting personalized neuromodulation dosing and software-delivered therapies for chronic cardiovascular, neurological, and metabolic conditions.
BIOS serves pharmaceutical companies, medical device manufacturers (particularly neuromodulation device makers), healthcare providers, and academic medical centers. Revenue is generated through long-term co-development partnerships (subscription/recurring), clinical trial data services (professional services), and licensing of the NeuroTune platform, with multi-year contracts and quote-based pricing disclosed as the standard engagement model. The company is supported by a deep research and grant ecosystem spanning NIH (REVEAL $21M project), SPARC-NIH ($1.4M grant plus Neuromod Prize), Canadian collaborations with Mila/McGill/Universit\u00e9 de Montr\u00e9al (cumulative CA$2.6M), the NHS, and a board chaired by IQVIA's VP of Genomic and Precision Medicine. Operationally, BIOS maintains hubs in Cambridge (headquarters), Montreal (AI R&D at Mila), and Bakersfield, California (US clinical and commercial hub established January 2024), and in 2026 spun out a majority-owned subsidiary, Kordata Dynamics, to commercialize an AI-powered precision clinical trials platform built on BIOS's NeuroTune IP.
BIOS firmographics
Firmographics- Name
- BIOS
- Legal name
- BIOS Health Ltd
- Website
- https://bios.health
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BIOS Health is a UK-based neural engineering company that builds AI-driven neural interfaces and an AI dosing platform (NeuroTune) to read and write the body's nervous system signals in real time, serving pharmaceutical firms, neuromodulation device makers, healthcare providers, and academic medical centers.
- Ownership category
- akta.pro rank
BIOS industry classification
Industry- Product category
- Neural Engineering / Bioelectronic Medicine Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where BIOS is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
BIOS business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Revenue model
- Technology Partnerships with Pharma/MedTech: Long-term partnerships for co-development of neural digital therapies with pharmaceutical and medical device companies. BIOS technology enables real-time insights into how pharmaceuticals affect the nervous system, cutting feedback time on efficacy results from months to minutes.
- Clinical Trial Services: Providing neural data analysis services for clinical trials, enabling pharmaceutical companies to reduce trial timelines and improve success rates through real-time neural response monitoring.
- NeuroTune Platform Licensing: Making BIOS NeuroTune available to select clinical and preclinical partners for personalized dosing optimization of neuromodulation devices.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise partnership model - custom pricing based on scope |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
BIOS product offering
Product offeringCore offering
BIOS Health develops an AI-driven neural interface platform that reads and writes nervous system signals in real-time to enable neural digital therapies. The company sells co-development partnerships, clinical trial data services, and licensing of its NeuroTune dosing AI platform to pharmaceutical, medical device, and clinical research partners, with a primary focus on autonomic and neuromodulation therapies for chronic diseases.
Differentiator
Problem solved
Functional benefit
Brands
- NeuroTune: BIOS NeuroTune is the company's dosing AI co-pilot that personalizes neuromodulation device settings in under ten minutes. The algorithms dynamically model a patient or subject's neural and physiological responses to stimulations and suggest personalized parameters.
- Autonomic Therapy Initiative (ATI)
- Remote Health Platform (RHP)
Products and services
- NeuroTune (Neural Dosing Platform) AI-powered dosing co-pilot that personalizes neuromodulation device settings in under 10 minutes. Dynamically models patient neural and physiological responses to stimulations and suggests personalized parameters. For researchers, accelerates therapy discovery by assessing thousands of unique stimulations in a single trial.
- Neural Biomarker Discovery Platform Technology platform that precisely links nerve activity to specific chronic conditions by isolating neural biomarkers of disease and responding to them in real-time. Enables reading and writing the body's neural signals to understand and correct faulty signals causing disease.
- Remote Health Platform (RHP) Medical device platform combining wearable devices and mobile apps to monitor patient health remotely. Collects biomarkers and cardiac metrics including ECG, PPG, accelerometer, respiratory pressure, and blood glucose data to deliver personalized and responsive neural digital therapies.
- Autonomic Therapy Initiative (ATI) Programme initiative to develop neural digital therapies for cardiovascular diseases using AI-powered neural interfaces. Works with world-leading partners to deliver new treatments for heart disease through real-time neural signal analysis and closed-loop neuromodulation.
- Clinical Trial Neural Data Services Service offering that provides neural data analysis for pharmaceutical clinical trials, enabling real-time neural response monitoring, adaptive dosing optimization, and reduced trial timelines by cutting efficacy feedback time from months to minutes.
Quantifiable outcome
- Reduces neuromodulation device optimization from 12 months to under 10 minutes
- +3 more outcomes
Companies that use BIOS
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
BIOS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature4 records
BIOS partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered core, minor and flagship.
- City of BakersfieldcorePartnered with KVG and Kern County to establish BIOS West Coast precision medicine hub. Approved $250K grant for BIOS to establish first US clinical and commercial hub.
- Kern CountycorePartnered with City of Bakersfield and KVG to attract BIOS to the region. Part of economic development initiative for biotech and AI sector growth.
- Cal State BakersfieldminorPartnership to develop trained workers for BIOS precision medicine hub in Bakersfield.
- National Institutes of Health (NIH)flagshipBIOS technology selected to power the $21M REVEAL project - the largest ever single clinical study of human neural data. BIOS provides software infrastructure for analyzing neural data from 150 patients across 8 global clinics over 3 years, investigating neural therapies for chronic diseases.
- University of MinnesotaflagshipLead institution for NIH REVEAL project. Principal Investigator John Osborn leads the consortium. Study focuses on vagus nerve physiology and neural therapies for cardiovascular, metabolic, immune, and autonomic nervous systems.
- Mayo CliniccoreClinical partner in REVEAL project, contributing to research on neural therapies for chronic diseases including heart failure, epilepsy, and respiratory conditions.
- Stanford UniversitycoreClinical partner in NIH REVEAL project, contributing expertise to neural biomarker research and vagus nerve stimulation therapies.
- MUSC HealthminorAcademic health system partner in REVEAL consortium for neural therapies research.
- Washington University in St. LouisminorAcademic partner in NIH REVEAL project consortium.
- Sheppard PrattminorMental health system partner in REVEAL project consortium.
- Scuola Superiore Sant'Anna (Italy)minorEuropean academic partner in REVEAL project for vagus nerve research.
- Baker Heart and Diabetes InstituteminorAustralian research partner in REVEAL consortium for neural-cardiac research.
- Mila (Montreal AI Institute)coreBIOS opened R&D office at Mila in 2018 to leverage Montreal's AI talent. Partnership to develop AI-controlled closed-loop neuromodulation system for chronic cardiac conditions. Extended in 2022 with CA$1.8M funding.
- McGill UniversitycoreResearch partnership with Dr. Blake Richards (School of Computer Science) to use machine learning to identify relationships between cardiac activity and neural signals. Part of CA$800K and CA$1.8M initiatives.
- Université de MontréalcoreResearch partnership with Dr. Guillaume Lajoie (Applied Mathematics) to optimize neural interface system for decoding and encoding brain-to-body signals. Part of neuro-cardiology AI collaboration.
- NVIDIAcoreNVIDIA GPUs used for BIOS AI and machine learning processing. Listed as selected partner on website footer.
- NHScoreUK National Health Service partnership for clinical trials. BIOS conducted remote trials with NHS during COVID-19 pandemic.
- SPARC (Stimulating Peripheral Activity to Relieve Conditions)flagshipNIH Common Fund program. Awarded BIOS $1.4M grant in 2021 and BIOS won $100K Neuromod Prize Phase 1. BIOS technology powers SPARC objectives for neural treatment development.
Scale indicators10 records
Recent moves9 records
Expansion highlights6 records
BIOS competitors and assessment
Company assessmentDirect peers
- Synchron: Synchron develops brain-computer interface technology (Stentrode) for patients with paralysis, similar to BIOS's neural interface focus. Both target chronic disease through neural signal interpretation, though Synchron emphasizes motor restoration while BIOS targets therapy dosing and digital therapeutics.
- Blackrock Neurotech: Blackrock Neurotech builds neural interface platforms for research and clinical applications, with similar focus on reading/writing neural signals. Both companies pursue chronic disease applications through neural data, with comparable hardware-software-AI integrated offerings.
- Saluda Medical: Saluda Medical develops closed-loop neuromodulation devices (Evoke system) that use real-time neural feedback to personalize spinal cord stimulation. Closely aligned with BIOS's NeuroTune AI dosing platform philosophy of automating and personalizing neuromodulation parameters via neural signal analysis.
- Setpoint Medical: Setpoint Medical develops bioelectronic medicine targeting inflammatory diseases through vagus nerve stimulation. Highly comparable to BIOS's Autonomic Therapy Initiative (ATI) approach of using neural interfaces and AI to treat chronic inflammatory and autoimmune conditions.
- Neuralink: Neuralink develops implantable brain-computer interfaces with AI-driven signal processing for medical and consumer applications. While Neuralink focuses on higher-bandwidth cortical interfaces and BIOS on peripheral/autonomic neural interfaces, both pursue the same fundamental vision of reading/writing neural code.
Broad incumbents
- Medtronic: Medtronic is the largest neuromodulation device company with established vagus nerve stimulation, deep brain stimulation, and spinal cord stimulation franchises. BIOS's NeuroTune could either compete with or license into Medtronic's installed base, making Medtronic both a potential partner and competitor.
- Boston Scientific: Boston Scientific (via LivaNova acquisition) offers Vagus Nerve Stimulation therapy for epilepsy and depression, directly overlapping BIOS's ATI therapeutic targets. As a broad incumbent, Boston Scientific has the regulatory, commercial, and clinical infrastructure to either compete with or partner with BIOS.
- Abbott: Abbott's neuromodulation division (formerly St. Jude Medical) markets Proclaim DRG and Prodigy MRI neurostimulation systems for chronic pain. As a broad incumbent with established hospital sales channels, Abbott could either license BIOS's AI dosing or compete with proprietary closed-loop capabilities.
Emerging players
- Insitro: Insitro uses AI/ML for drug discovery and development, addressing pharma R&D productivity similar to BIOS's clinical trial neural monitoring service. Both target pharmaceutical companies with AI-driven platforms, though Insitro focuses on in silico biology while BIOS focuses on neural signal interpretation.
- Recursion Pharmaceuticals: Recursion uses AI/ML for high-throughput drug discovery and is building clinical trial optimization capabilities. While Recursion operates in a different therapeutic modality (small molecule + phenotypic screening), it overlaps with BIOS on AI-enabled clinical trial efficiency for pharma customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
BIOS social profiles
Digital presenceBIOS financial estimates
Financial estimateRevenue estimate
Valuation estimate
BIOS leadership team
Management profileNumber of profiles
Profiles9 records
BIOS subsidiaries and ownership
Company hierarchySubsidiaries1 record
BIOS funding detail
Funding detailFunding overview
Funding rounds11 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BIOS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BIOS
What does BIOS do?
BIOS Health develops an AI-driven neural interface platform that reads and writes nervous system signals in real-time to enable neural digital therapies. The company sells co-development partnerships, clinical trial data services, and licensing of its NeuroTune dosing AI platform to pharmaceutical, medical device, and clinical research partners, with a primary focus on autonomic and neuromodulation therapies for chronic diseases.
Is BIOS a public or private company?
BIOS is a private company. It is classified as venture growth investor backed and is currently operating.
When was BIOS founded?
BIOS was founded in 2015. It employs 11 to 50 people.
Where is BIOS based?
BIOS is headquartered in Cambridge, United Kingdom, in the Europe region.
How does BIOS make money?
Three revenue lines are on record. Technology Partnerships with Pharma/MedTech is the primary driver. The others are clinical Trial Services and neuroTune Platform Licensing.
Who are BIOS's main competitors?
Direct peers on record are Synchron, Blackrock Neurotech, Saluda Medical, Setpoint Medical and Neuralink. Broad incumbents are Medtronic, Boston Scientific and Abbott. Emerging players are Insitro and Recursion Pharmaceuticals.
Does BIOS have an API?
No public API is recorded for BIOS.
What industry is BIOS in?
BIOS's product category is Neural Engineering / Bioelectronic Medicine Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 541714 and its SIC code is 8731.